Panacea Biotec Ltd has entered into collaboration with UK-based Cambridge Biostability Ltd for manufacturing of vaccines using stable liquid technology' which will revolutionise vaccine delivery by eliminating the need for refrigeration, the company announced here.
Meantime, the company said that it had launched Lower (The Ezetimibe - Atorvastatin Combination) for Intensive Cholesterol Management in patients who are at high risk of developing Cardiovascular Disease (CVD) & Stroke in the 56th Annual Conference of Cardiological Society of India, Bangalore.
Dr. V T Shah, Consultant Cardiologist, Jaslok Hospital, Mumbai, presented a Multi-centric phase III study of over 100 patients in India, conducted to evaluate the efficacy and safety of Lower in hyperlipidemic patients in the 56th Annual Conference of Cardiological Society of India, Bangalore.
The result of this study shows that Lower (The Ezetimibe - Atorvastatin Combination) was able to reduce LDL (bad cholesterol) below 100 mgm (NCEP ATP III targets) in 89 per cent of patients, the company said here.
Pravin Kumar, VP, Sales & Mktg stated, "Lower has pronounced efficacy in not only aggressively lowering LDL (bad cholesterol) by 41 per cent but also significantly reducing Triglycerides by 25 per cent & improving HDL (good cholesterol) levels by 11 per cent. Lower is effective in lowering hs-CRP levels resulting in significant anti-inflammatory effect."